現(xiàn)任上海大學(xué)醫(yī)學(xué)院副院長，上海大學(xué)細(xì)胞治療創(chuàng)新研究院院長，上海細(xì)胞治療研究院院長，上海細(xì)胞治療工程技術(shù)研究中心主任，上海吳孟超聯(lián)合諾貝爾獎(jiǎng)獲得者醫(yī)療科技創(chuàng)新中心主任，上海細(xì)胞治療集團(tuán)董事長兼總裁。

國家杰出青年科學(xué)基金獲得者，國家重點(diǎn)研發(fā)計(jì)劃項(xiàng)目精準(zhǔn)醫(yī)療專項(xiàng)首席科學(xué)家，上海市優(yōu)秀學(xué)科帶頭人，上海市領(lǐng)軍人才，上海市“五一勞動(dòng)獎(jiǎng)?wù)隆鲍@得者�，F(xiàn)任中國生物醫(yī)藥技術(shù)協(xié)會(huì)精準(zhǔn)醫(yī)療分會(huì)、中國醫(yī)藥質(zhì)量管理協(xié)會(huì)細(xì)胞治療質(zhì)量控制與研究專業(yè)委員會(huì)等8個(gè)行業(yè)學(xué)會(huì)的副主任委員。

先后主持承擔(dān)國家科技重大專項(xiàng)、863項(xiàng)目、國自然杰青、海外杰青、重大項(xiàng)目、重點(diǎn)項(xiàng)目、面上項(xiàng)目等國家級(jí)課題16項(xiàng)。獲國家科學(xué)技術(shù)進(jìn)步創(chuàng)新團(tuán)隊(duì)獎(jiǎng)1項(xiàng)，省部級(jí)二等獎(jiǎng)4項(xiàng)，三等獎(jiǎng)3項(xiàng)。共發(fā)表SCI論文83篇；已申請(qǐng)217項(xiàng)細(xì)胞治療相關(guān)專利,獲專利授權(quán)47項(xiàng)，其中美國發(fā)明專利2 項(xiàng)。

主要從事腫瘤精準(zhǔn)細(xì)胞免疫治療，包括：精準(zhǔn)細(xì)胞免疫治療臨床應(yīng)用、精準(zhǔn)細(xì)胞免疫治療新技術(shù)研發(fā)、精準(zhǔn)免疫細(xì)胞儲(chǔ)存、基因檢測、精準(zhǔn)細(xì)胞臨床級(jí)規(guī)模制備及相關(guān)設(shè)備的研發(fā)。目前團(tuán)隊(duì)正在研發(fā)細(xì)胞玄鐵劍：采用非病毒載體進(jìn)行基因修飾的新一代CAR-T；細(xì)胞六脈神劍：PNA-T精準(zhǔn)殺滅癌細(xì)胞；細(xì)胞倚天劍：PIK-T，通過表達(dá)免疫檢查點(diǎn)抗體如抗PD-1抗體來改變癌癥微環(huán)境，解除對(duì)免疫細(xì)胞的抑制，通過非病毒載體、納米抗體及mRNA技術(shù)來實(shí)現(xiàn)三劍合一的白澤劍技術(shù)及超級(jí)白澤T細(xì)胞。2019年4月申報(bào)項(xiàng)目以CD19為靶點(diǎn)的CAR-T細(xì)胞治療新藥獲得國家藥監(jiān)局許可開展臨床實(shí)驗(yàn)，是目前國內(nèi)第一家通過許可的以非病毒載體制備的CAR-T細(xì)胞治療產(chǎn)品進(jìn)入臨床。

為最早提出腫瘤基因－病毒治療新策略研究者之一，該策略結(jié)合了傳統(tǒng)的腫瘤基因治療與病毒治療的雙重優(yōu)勢，體內(nèi)外實(shí)驗(yàn)證明該策略的療效明顯優(yōu)于單一的基因治療與病毒治療，在此基礎(chǔ)上研發(fā)了一種腺病毒生產(chǎn)純化平臺(tái)，為國內(nèi)上百家單位提供腺病毒技術(shù)支持。最早成功利用腺病毒載體系統(tǒng)高效表達(dá)全長抗體，在國際首次提出全長抗體基因治療策略。

1、癌癥戰(zhàn)爭之克癌新道 2020-03 中國科學(xué)技術(shù)出版社

2、癌癥戰(zhàn)爭 2014-10 中國科學(xué)技術(shù)出版社

3、Therapeutic Cancer Vaccines

1.新的癌癥靶向基因-病毒治療（CTGVT）2013年獲上海市科學(xué)技術(shù)獎(jiǎng)二等獎(jiǎng)劉新垣　錢其軍　吳孟超　顧錦法　錢　程

2.第二軍醫(yī)大學(xué)肝癌臨床與基礎(chǔ)集成化研究創(chuàng)新團(tuán)隊(duì)2012年國家科學(xué)技術(shù)進(jìn)步獎(jiǎng)

3.攜帶治療基因的特異性增殖型腺病毒在肝癌中的實(shí)驗(yàn)性研究廣州軍區(qū)廣州總醫(yī)院上海東方肝膽外科醫(yī)院2011年廣東省科學(xué)技術(shù)進(jìn)步三等獎(jiǎng)彭林輝、錢其軍、蘇長青、張琪、詹世林、石英、陳建雄

4.腫瘤基因-病毒治療中國人民解放軍第二軍醫(yī)大學(xué)第三附屬醫(yī)院中國科學(xué)院上海生命科學(xué)院生化與細(xì)胞研究所、浙江理工大學(xué)2005年上海市科學(xué)技術(shù)進(jìn)步二等獎(jiǎng)錢其軍、劉新垣、吳孟超、張琪、顧錦法

5.腫瘤靶向基因-病毒治療中國人民解放軍第二軍醫(yī)大學(xué)第三附屬醫(yī)院中國科學(xué)院上海生命科學(xué)院生化與細(xì)胞研究所、浙江理工大學(xué)2005年上海市醫(yī)學(xué)獎(jiǎng)二等獎(jiǎng)錢其軍、劉新垣、吳孟超、張琪、顧錦法

6.腫瘤靶向基因-病毒治療中國人民解放軍第二軍醫(yī)大學(xué)第三附屬醫(yī)院中國科學(xué)院上海生命科學(xué)院生化與細(xì)胞研究所、浙江理工大學(xué)2005年中華醫(yī)學(xué)科技獎(jiǎng)三等獎(jiǎng)錢其軍、劉新垣、吳孟超、張琪、顧錦法

7.穿孔素和顆粒酶B基因?qū)Ω我浦布毙耘懦庠缙谠\斷的實(shí)驗(yàn)研究　中國人民解放軍南京軍區(qū)福州總醫(yī)院、中國人民解放軍第二軍醫(yī)大學(xué)第三附屬醫(yī)院　2004福建省科學(xué)技術(shù)進(jìn)步二等獎(jiǎng)，張紹庚、談景旺、錢其軍、楊甲梅、吳孟超

8.脾內(nèi)轉(zhuǎn)染白介素12及白介素2基因?qū)Ω伟┑幕�因治療上海市科學(xué)技術(shù)進(jìn)步三等獎(jiǎng)，2003年（排名第二）楊家和、錢其軍、尤天庚、范瑞芳、蘇長青、薛惠斌、李楠

Wen W, Song S, Han Y, Chen H, Liu X, Qian Q. An efficient Screening System in Yeast to Select a Hyperactive piggyBac Transposase for Mammalian Applications. Int J Mol Sci. 2020;21(9):3064. Published 2020 Apr 26. doi:10.3390/ijms21093064Chen C, Aldarouish M, Li Q, Liu X, Han F, Liu H, Qian Q. Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine. J Immunol Res. 2020;2020:3965061. Published 2020 Apr 4. doi:10.1155/2020/3965061Qiu J, Zhou F, Li X, Zhang S, Chen Z, Xu Z, Lu G, Zhu Z, Ding N, Lou J, Ye Z, Qian Q. Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients. Cancer Manag Res. 2020;12:209-219. Published 2020 Jan 9. doi:10.2147/CMAR.S221586Zhang M, Yang J, Hua W, Li Z, Xu Z, Qian Q. Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. Front Med. 2019;13(1):32-44. doi:10.1007/s11684-018-0678-0Ye Z, Ding Y, Chen Z, Li Z, Ma S, Xu Z, Cheng L, Wang X, Zhang X, Ding N, Zhang Q, Qian Q. Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. Cancer Biol Ther. 2019;20(4):546-551. doi:10.1080/15384047.2018.1538000Zhang Z, Jiang D, Yang H, He Z, Liu X, Qin W, Li L, Wang C, Li Y, Li H, Xu H, Jin H, Qian Q. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor [published correction appears in Cell Death Dis. 2020 Apr 16;11(4):235]. Cell Death Dis. 2019;10(7):476. Published 2019 Jun 17. doi:10.1038/s41419-019-1711-1Zhuang Y, Zhang C, Wu Q, Zhang J, Ye Z, Qian Q. Application of immune repertoire sequencing in cancer immunotherapy. Int Immunopharmacol. 2019;74:105688. doi:10.1016/j.intimp.2019.105688Wang P, Qin W, Liu T, Jiang D, Cui L, Liu X, Fang Y, Tang X, Jin H, Qian Q. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma. Immunobiology. 2020;225(1):151850. doi:10.1016/j.imbio.2019.09.009Huang Y, Lv SQ, Liu PY, Ye ZL, Yang H, Li LF, Zhu HL, Wang Y, Cui LZ, Jiang DQ, Hao FY, Xu HM, Jin HJ, Qian QJ. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer. Mol Oncol. 2020;14(3):657-668. doi:10.1002/1878-0261.12628Ye Z, Qian Q, Jin H, Qian Q. Cancer vaccine: learning lessons from immune checkpoint inhibitors. J Cancer. 2018;9(2):263-268. Published 2018 Jan 1. doi:10.7150/jca.20059Wang Y, Yang X, Yu Y, Xu Z, Sun Y, Liu H, Cheng J, Liu M, Sha B, Li L, Ding N, Li Z, Jin H, Qian Q. Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes ex vivo activated with tumor antigen-pulsed dendritic cells. J Cancer. 2018;9(2):275-287. Published 2018 Jan 1. doi:10.7150/jca.22176Li H, Huang Y, Jiang DQ, Cui LZ, He Z, Wang C, Zhang ZW, Zhu HL, Ding YM, Li LF, Li Q, Jin HJ, Qian QJ. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 2018;9(2):177. Published 2018 Feb 7. doi:10.1038/s41419-017-0238-6He J, Zhang Z, Lv S, Liu X, Cui L, Jiang D, Zhang Q, Li L, Qin W, Jin H, Qian Q. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer. Cell Immunol. 2018;329:31-40. doi:10.1016/j.cellimm.2018.04.007Xu JY, Ye ZL, Jiang DQ, He JC, Ding YM, Li LF, Lv SQ, Wang Y, Jin HJ, Qian QJ. Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. Tumour Biol. 2017;39(4):1010428317695949. doi:10.1177/1010428317695949Wang Y, Ding M, Zhang Q, Wang J, Yang X, Zhou F, Li L, Yuan Z, Jin H, Qian Q. Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis. J Cancer. 2017;8(1):74-84. Published 2017 Jan 1. doi:10.7150/jca.16774Lv SQ, Ye ZL, Liu PY, Huang Y, Li LF, Liu H, Zhu HL, Jin HJ, Qian QJ. 11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity. J Cancer. 2017;8(2):199-206. Published 2017 Jan 13. doi:10.7150/jca.16406Ye Z, Li Z, Jin H, Qian Q. Therapeutic Cancer Vaccines. Adv Exp Med Biol. 2016;909:139-167. doi:10.1007/978-94-017-7555-7_3Zhang H, Ye ZL, Yuan ZG, Luo ZQ, Jin HJ, Qian QJ. New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci. 2016;12(6):718-729. Published 2016 Apr 28. doi:10.7150/ijbs.14405Ye Z, Jin H, Qian Q. Argonaute 2: A Novel Rising Star in Cancer Research. J Cancer. 2015;6(9):877-882. Published 2015 Jul 16. doi:10.7150/jca.11735Ye ZL, Huang Y, Li LF, Zhu HL, Gao HX, Liu H, Lv SQ, Xu ZH, Zheng LN, Liu T, Zhang JL, Jin HJ, Qian QJ. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma [published correction appears in Acta Pharmacol Sin. 2018 Feb;39(2):329]. Acta Pharmacol Sin. 2015;36(10):1237-1245. doi:10.1038/aps.2015.18Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L, Jin H, Qian Q. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol. 2015;4:32. Published 2015 Nov 10. doi:10.1186/s40164-015-0027-9Li J, Yu Y, Wang J, Yan Z, Liu H, Wang Y, Ding M, Cui L, Wu M, Jiang X, Qian Q. Establishment of a novel system for the culture and expansion of hepatic stem-like cancer cells. Cancer Lett. 2015;360(2):177-186. doi:10.1016/j.canlet.2015.02.006Ding M, LiJ, Yu Y, Liu H, Yan Z, Wang J,Qian Q. Integrated analysis of miRNA, gene, and pathwayregulatory networks in hepatic cancer stem cells.J Transl Med.2015;13:259. Published 2015 Aug 11. doi:10.1186/s12967-015-0609-7Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, Zhang J, Fu S, Xie D, Wu M, Zhou W, Qian Q. MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis. 2014;3(4):e97. Published 2014 Apr 14. doi:10.1038/oncsis.2014.11Peng X, Liu T, Shi C, Zhang L, Wang Y, Zhao W, Jiang L, Wu M, Zhang Y, Qian Q. Germline transmission of an embryonic stem cell line derived from BALB/c cataract mice. PLoS One. 2014;9(3):e90707. Published 2014 Mar 4. doi:10.1371/journal.pone.0090707Hong J, Jin H, Han J, Hu H, Liu J, Li L, Huang Y, Wang D, Wu M, Qiu L, Qian Q. Infusion of human umbilical cord derived mesenchymal stem cells effectively relieves liver cirrhosis in DEN induced rats. Mol Med Rep. 2014;9(4):1103-1111. doi:10.3892/mmr.2014.1927Tong Y, You L, Liu H, Li L, Meng H, Qian Q, Qian W. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget. 2013;4(6):860-874. doi:10.18632/oncotarget.1018Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu J, Qian QJ, Wang HY, Ying QL. DNA damage-induced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats. Oncogene. 2013;32(38):4565-4571. doi:10.1038/onc.2012.451Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H, Qian QJ, Wang HY, Ying QL. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol. 2013;59(4):762-768. doi:10.1016/j.jhep.2013.05.029Wang J, Yu Y, Yan Z, Hu Z, Li L, Li J, Jiang X, Qian Q. Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo. Oncol Rep. 2013;30(2):833-841. doi:10.3892/or.2013.2511Wang J, Li L, Zhang K, Yu Y, Li B, Li J, Yan Z, Hu Z, Yen Y, Wu M, Jiang X, Qian Q. Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. PLoS One. 2013;8(1):e54377. doi:10.1371/journal.pone.0054377Peng X, Liu T, Yang B, Shi C, Sun Y, Jiang L, Jin H, Li L, Zhu H, Wu M, Qian Q. Germ-line-competent embryonic stem cells of the Chinese Kunming mouse strain with long-term self-renewal ability. Cell Reprogram. 2013;15(3):179-184. doi:10.1089/cell.2012.0065Peng X, Gao H, Wang Y, Yang B, Liu T, Sun Y, Jin H, Jiang L, Li L, Wu M, Qian Q. Conversion of rat embryonic stem cells into neural precursors in chemical-defined medium. Biochem Biophys Res Commun. 2013;431(4):783-787. doi:10.1016/j.bbrc.2013.01.023Li J, Liu H, Li L, Wu H, Wang C, Yan Z, Wang Y, Su C,Jin H, Zhou F, Wu M,Qian Q. Thecombination of an oxygen-dependent degradation domain-regulated adenovirusexpressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumoractivity in hepatocellular carcinoma.Oncol Rep.2013;29(3):895-902. doi:10.3892/or.2012.2217Wang JH, Li LF, Yu Y, Li B, Jin HJ, Shen DH, Li J,Jiang XQ,Qian QJ.Establishment and characterization of a cell line, EH-GB2, derived from hepaticmetastasis of gallbladder cancer.Oncol Rep. 2012;27(3):775-782.doi:10.3892/or.2011.1570Peng X, Liu T, Wang Y, Yan Q, Jin H, Li L, Qian Q, Wu M. Wnt/beta-catenin signaling in embryonic stem cell converted tumor cells. J Transl Med. 2012;10:196. Published 2012 Sep 20. doi:10.1186/1479-5876-10-196Liu XR, Cai Y, Cao X, Wei RC, Li HL, Zhou XM, Zhang KJ, Wu S, Qian QJ, Cheng B, Huang K, Liu XY. A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect. J Cell Mol Med. 2012;16(6):1298-1309. doi:10.1111/j.1582-4934.2011.01396.xLiu T, Wang Y, Peng X, Zhang L, Cheng J, Jin H, Wu M, Qian Q. Establishment of mouse teratocarcinomas stem cells line and screening genes responsible for malignancy. PLoS One. 2012;7(8):e43955. doi:10.1371/journal.pone.0043955Wei RC, Cao X, Gui JH, Zhou XM, Zhong D, Yan QL, Huang WD, Qian QJ, Zhao FL, Liu XY. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Hum Gene Ther. 2011;22(9):1109-1119. doi:10.1089/hum.2010.219Liu X, Qian Q, Xu P, Wolf F, Zhang J, Zhang D, Li C, Huang Q. A novel conditionally replicating "armed" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling. Hum Gene Ther. 2011;22(4):427-437. doi:10.1089/hum.2010.128Jin H, Lv S, Yang J, Wang X, Hu H, Su C, Zhou C, Li J, Huang Y, Li L, Liu X, Wu M, Qian Q. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells. PLoS One. 2011;6(7):e21307. doi:10.1371/journal.pone.0021307Ji W, Yang J, Wang D, Cao L, Tan W, Qian H, Sun B, Qian Q, Yin Z, Wu M, Su C. hSulf-1 gene exhibits anticancer efficacy through negatively regulating VEGFR-2 signaling in human cancers. PLoS One. 2011;6(8):e23274. doi:10.1371/journal.pone.0023274Hu H, Li Z, Chen J, Wang D, Ma J, Wang W, Li J, Wu H, Li L, Wu M, Qian Q, Chen J, Su C. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2011;60(5):710-721. doi:10.1136/gut.2010.220020He X, LiuJ, Yang C, Su C, Zhou C, Zhang Q, Li L, Wu H, Liu X, Wu M,Qian Q. 5/35fiber-modified conditionally replicative adenovirus armed with p53 showsincreased tumor-suppressing capacity to breast cancer cells.Hum GeneTher. 2011;22(3):283-292.doi:10.1089/hum.2010.058Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q, Chen G. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma. Cancer Lett. 2011;307(1):93-103. doi:10.1016/j.canlet.2011.03.021Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, Yang DQ, Li HL, Ding M, Wei N, Zhang KJ, Xu B, Liu XR, Qian QJ, Liu XY. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther. 2011;18(8):765-777. doi:10.1038/gt.2011.16Yu DB, Zhong SY, Yang M, Wang YG, Qian QJ, Zheng S, Liu XY. Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer. Cancer Sci. 2009;100(4):678-683. doi:10.1111/j.1349-7006.2009.01110.xYao Y, Jia XY, Tian HY, Jiang YX, Xu GJ,Qian QJ, Zhao FK.Comparative proteomic analysis of colon cancer cells in response to oxaliplatintreatment.Biochim Biophys Acta. 2009;1794(10):1433-1440.doi:10.1016/j.bbapap.2009.06.005Xu Z, Jin H, Qian Q. Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases. Expert Opin Ther Pat. 2009;19(7):1035-1037. doi:10.1517/13543770902835525Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ, Ruan GR. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis. 2009;14(9):1086-1094. doi:10.1007/s10495-009-0373-3Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med. 2009;11(6):477-485. doi:10.1002/jgm.1326Rebetz J, Na M, Su C, Holmqvist B, Edqvist A, Nyberg C, Widegren B, Salford LG, Sj?gren HO, Arnberg N, Qian Q, Fan X. Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence. PLoS One. 2009;4(12):e8484. Published 2009 Dec 29. doi:10.1371/journal.pone.0008484Jin J, Liu H, Yang C, Li G, Liu X, Qian Q, Qian W. Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther. 2009;8(5):1387-1397. doi:10.1158/1535-7163.MCT-08-0962Guo M, Kang B, Zheng Q, Qian Q, Su C, Wu M, Yang J. An anti-preS2 antibody protects human hepatocytes from hepatitis B virus infection. Acta Gastroenterol Belg. 2009;72(3):306-311.Xu, Z., Zhou, X., Shi, Qian Q. Capsid modification of adeno-associated virus and tumor targeting gene therapy. Chin. Sci. Bull. 53, 3790u20133797 (2008). doi.org/10.1007/s11434-008-0487-yWang X, SuC, Cao H, Li K, Chen J, Jiang L, Zhang Q, Wu X, Jia X, Liu Y, Wang W, Liu X, WuM, Qian Q. A novel triple-regulated oncolytic adenoviruscarrying p53 gene exerts potent antitumor efficacy on common human solidcancers. Mol Cancer Ther. 2008;7(6):1598-1603. doi:10.1158/1535-7163.MCT-07-2429Su C, Na M,Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M, Fan X,Qian Q. Gene-viral cancer therapy using dual-regulatedoncolytic adenovirus with antiangiogenesis gene for increased efficacy.MolCancer Res. 2008;6(4):568-575. doi:10.1158/1541-7786.MCR-07-0073Su C, Cao H, Tan S, Huang Y, Jia X, Jiang L, Wang K, Chen Y, Long J, Liu X, Wu M, Wu X, Qian Q. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci. 2008;106(1):242-250. doi:10.1093/toxsci/kfn168Liu J, Ma L N, Wang Y G, Liu X Y, Qian Q J. A novel strategy for cancer treatment: Targeting cancer stem cells. Chin. Sci. Bull. 53, 1777u20131783 (2008). doi.org/10.1007/s11434-008-0241-5Li YM, Song ST, Jiang ZF, Zhang Q, Su CQ, Liao GQ, Qu YM, Xie GQ, Li MY, Ge FJ, Qian QJ. Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma. World J Gastroenterol. 2008;14(8):1274-1279. doi:10.3748/wjg.14.1274Chen J, Su C, Lu Q, Shi W, Zhang Q, Wang X, Long J,Yang Q, Li L, Jia X, Wang J, Da W, Liu X, Wu M,Qian Q. Generation of adenovirus-mediated anti-CD20 antibodyand its effect on B-cell deletion in mice and nonhuman primate cynomolgusmonkey.Mol Cancer Ther. 2008;7(6):1562-1568.doi:10.1158/1535-7163.MCT-08-0297Chu L, Gu J, Sun L, Qian Q, Qian C, Liu X. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Gene Ther. 2008;15(7):484-494. doi:10.1038/gt.2008.6Zhang Q,Chen G, Liu X,Qian Q. Monoclonalantibodies as therapeutic agents in oncology and antibody gene therapy.CellRes. 2007;17(2):89-99.doi:10.1038/sj.cr.7310143Shi W, Qu C, Qian Q. Trends in therapeutic monoclonal antibodies of cancer. Expert Opin Ther Pat. 2007;17(9):1047-1059. doi:10.1517/13543776.17.9.1047Zhang Y, Gu J, Zhao L, He L, Qian W, Wang J, Wang Y, Qian Q, Qian C, Wu J, Liu XY. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res. 2006;66(8):4291-4298. doi:10.1158/0008-5472.CAN-05-1834Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, Liu X. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther. 2006;13(11):1011-1022. doi:10.1038/sj.cgt.7700969Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Clin Cancer Res. 2006;12(21):6523-6531. doi:10.1158/1078-0432.CCR-06-1491Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo. J Gene Med. 2006;8(10):1232-1242. doi:10.1002/jgm.953Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J, Liu X, Wu M, Qian Q. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res. 2006;12(20 Pt 1):6179-6185. doi:10.1158/1078-0432.CCR-06-0746Su CQ, Wang XH, Chen J, Liu YJ, Wang WG, Li LF, Wu MC, Qian QJ. Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma. World J Gastroenterol. 2006;12(47):7613-7620. doi:10.3748/wjg.v12.i47.7613Su C, Peng L, Sham J, Wang X, Zhang Q, Chua D, Liu C, Cui Z, Xue H, Wu H, Yang Q, Zhang B, Liu X, Wu M, Qian Q. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Mol Ther. 2006;13(5):918-927. doi:10.1016/j.ymthe.2005.12.011Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L, Wang Y, Zhang J, Zhang Z, Huiwang J, Qian Q, Qian C, Liu X. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther. 2005;16(7):845-858. doi:10.1089/hum.2005.16.845Zhang Z, Zou W, Wang J, Gu J, Dang Y, Li B, Zhao L, Qian C, Qian Q, Liu X. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther. 2005;11(4):553-562. doi:10.1016/j.ymthe.2004.12.015Li GC, Yang JM, Nie MM, Su CG, Sun LC, Qian YZ, Fang GE, Sham J, Wu MC, Qian QJ. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma. Chin Med J (Engl). 2005;118(3):179-185.Li G, Sham J, Yang J, Su C, Xue H, Chua D, Sun L, Zhang Q, Cui Z, Wu M, Qian Q. Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int J Cancer. 2005;113(4):640-648. doi:10.1002/ijc.20581Zhang Q, Nie M, Sham J, Su C, Xue H, Chua D, Wang W, Cui Z, Liu Y, Liu C, Jiang M, Fang G, Liu X, Wu M, Qian Q. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene. Cancer Res. 2004;64(15):5390-5397. doi:10.1158/0008-5472.CAN-04-1229You TG, Wang HS, Yang JH, Qian QJ, Fan RF, Wu MC. Transfection of IL-2 and/or IL-12 genes into spleen in treatment of rat liver cancer. World J Gastroenterol. 2004;10(15):2190-2194. doi:10.3748/wjg.v10.i15.2190Su CQ, Sham J, Xue HB, Wang XH, Chua D, Cui ZF, Peng LH, Li LF, Jiang LH, Wu MC, Qian QJ. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol. 2004;130(10):591-603. doi:10.1007/s00432-004-0577-4Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003;13(6):481-489. doi:10.1038/sj.cr.7290191Yang JH, You TG, Li N, Qian QJ, Wang P, Yan ZL, Wu MC. Relationship between the imaging features and pathologic alteration in hepatoma of rats. World J Gastroenterol. 2003;9(1):69-72. doi:10.3748/wjg.v9.i1.69Qian Q, Sham J, Che X, Xu J, Xue H, Cui Z, Zhu B, Wu M. Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously. Chin Med J (Engl). 2002;115(8):1213-1217.Liu J, Zou WG, Lang MF, Luo J, Sun LY, Wang XN, Qian QJ, Liu XY. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter. Int J Oncol. 2002;21(3):661-666.Qian QJ, Xue HB, Qu ZQ, Fang SG, Cao HF, Wu MC. In situ detection of tumor infiltrating lymphocytes expressing perforin and fas ligand genes in human HCC. World J Gastroenterol. 1999;5(1):12-14. doi:10.3748/wjg.v5.i1.12Minghong Jiang, Wenfang Shi, Qi Zhang, Xinhua Wang, Minggao Guo,Zhenfu Cui, Changqin Su, Qing Yang, Yuemin Li, Jonathan Sham, Xinyuan Liu, Mengchao Wu, andQijun Qian.Gene Therapy for Her2 over-expression cancers using adenovirus mediated full-length anti-Her2 antibody. Clin Cancer Res 2006 Oct 15;12(20 Pt 1):6179-85Gencong Li，Jonathan Sham，Jiamei Yang，Changqing Shu，Huibin Xue，Daniel Chua，Lichen Sun，Qi Zhang，ZhenfuCui，Mengchao Wu，Qijun Qian. Potent antitumoral efficacy of an E1b 55kda-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma. Int J Cancer . 2005 Feb 10;113(4):640-8.